FIELD: medicine.
SUBSTANCE: invention relates to a method for the preliminary treatment of a subject with a severe form of von Willebrand’s disease before surgery, including the administration of a dose to the subject in the range from about 20 IU/kg to about 60 IU/kg of rVWF in the period from about 12 hours to about 24 hours before surgery, and in which factor VIII is not administered together with rVWF before surgery.
EFFECT: invention makes it possible to carry out preliminary treatment with a high degree of efficiency before surgery in a subject with a severe form of von Willebrand’s disease.
21 cl, 6 dwg, 69 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| GLP-2 PEPTIBODY FOR INTRODUCTION BEFORE, DURING OR AFTER SURGICAL INTERVENTION | 2018 |
|
RU2795594C2 |
| PREPARATION CONTAINING VIII FACTOR AND VON WILLEBRAND FACTOR PEPTIDES | 2015 |
|
RU2714154C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| TREATMENT METHODS FOR HEMOPHILIA A | 2019 |
|
RU2812863C2 |
| PHARMACEUTICAL COMPOSITIONS OF PEGYLATED LIPOSOMES AND COAGULATION FACTORS | 2015 |
|
RU2737291C2 |
| IMPROVED FVIII FUSION PROTEIN AND ITS USE | 2019 |
|
RU2789085C2 |
| METHODS AND PRODUCTS FOR PRODUCING AND DELIVERING NUCLEIC ACIDS | 2015 |
|
RU2714404C2 |
| NUCLEIC ACID MOLECULES AND WAYS OF USING THEM | 2018 |
|
RU2819144C2 |
| METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR TREATING BILE DUCT CANCER | 2019 |
|
RU2819802C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
